Chase Doyle


Authored Items

Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma

Multiple Myeloma, Web Exclusives

Chicago, IL—In patients with newly diagnosed multiple myeloma, the addition of daratumumab to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (ie, the KRd regimen) is showing promise as a frontline treatment regimen. According to the results of an open-label, phase 1b study presented at ASCO 2017, induction therapy with the KRd [ Read More ]

Recent FDA Approvals for ALL a “Watershed” Moment

Leukemia, Web Exclusives

Atlanta, GA—The past few years have witnessed significant progress in the treatment of several hematologic malignancies, and truly paradigm-changing therapies have recently emerged in acute lymphoblastic leukemia (ALL). At ASH 2017, Crystal L. Mackall, MD, Co-Director, Immunology & Immunotherapy of Cancer Program, Stanford University, CA, discussed the FDA approvals of [ Read More ]

Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern

Immunotherapy, Web Exclusives

Atlanta, GA—As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes. According to data presented at ASH 2017, 3 approaches are currently being explored, which include: Using immunotherapies to replace nonspecific cytotoxic agents to increase efficacy and reduce [ Read More ]

Sign me up!